CA2208859A1 - Utilisation de 3,4-diphenyl chromannes pour obtenir une composition pharmaceutique de traitement ou de prophylaxie de l'hyperlipoproteinemie, de l'hypertriglyceridemie, de l'hyperlipidemie, de l'hypercholesterolemie, de l'arteriosclerose, ou dans un traitement anticoagulant - Google Patents

Utilisation de 3,4-diphenyl chromannes pour obtenir une composition pharmaceutique de traitement ou de prophylaxie de l'hyperlipoproteinemie, de l'hypertriglyceridemie, de l'hyperlipidemie, de l'hypercholesterolemie, de l'arteriosclerose, ou dans un traitement anticoagulant

Info

Publication number
CA2208859A1
CA2208859A1 CA002208859A CA2208859A CA2208859A1 CA 2208859 A1 CA2208859 A1 CA 2208859A1 CA 002208859 A CA002208859 A CA 002208859A CA 2208859 A CA2208859 A CA 2208859A CA 2208859 A1 CA2208859 A1 CA 2208859A1
Authority
CA
Canada
Prior art keywords
treatment
prophylaxis
compound
use according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002208859A
Other languages
English (en)
Inventor
Michael Shalmi
Niels Korsgaard
Steven Bain
Birgitte Hjort Guldhammer
Jan Ulrik Weis
Charles E. Hart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2208859A1 publication Critical patent/CA2208859A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)

Abstract

On décrit de nouvelles utilisations de composés de formule I dans laquelle R1, R4 et R5 représentent individuellement hydrogène, hydroxy, halogène, trifluorométhyle, alkyle inférieur, alcoxy inférieur ou (alcoxy inférieur)(amino tertiaire); et R2 et R3 représentent individuellement hydrogène ou alkyle inférieur. Ces composés, ou un de leurs sels pharmaceutiquement acceptables, combinés avec un vecteur pharmacologiquement acceptable, permettent d'obtenir une composition pharmaceutique servant au traitement ou à la prophylaxie de l'hyperlipoprotéinémie, de l'hypertriglycéridémie, de l'hyperlipidémie, de l'hypercholestérolémie, de l'artériosclérose, ou bien ils servent de traitement anticoagulant.
CA002208859A 1995-01-13 1996-01-10 Utilisation de 3,4-diphenyl chromannes pour obtenir une composition pharmaceutique de traitement ou de prophylaxie de l'hyperlipoproteinemie, de l'hypertriglyceridemie, de l'hyperlipidemie, de l'hypercholesterolemie, de l'arteriosclerose, ou dans un traitement anticoagulant Abandoned CA2208859A1 (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
DK4195 1995-01-13
DK0043/95 1995-01-13
DK4395 1995-01-13
DK0041/95 1995-01-13
DK6995 1995-01-20
DK0069/95 1995-01-20
DK0766/95 1995-06-30
DK76795 1995-06-30
DK0767/95 1995-06-30
DK0777/95 1995-06-30
DK76695 1995-06-30
DK77795 1995-06-30

Publications (1)

Publication Number Publication Date
CA2208859A1 true CA2208859A1 (fr) 1996-07-18

Family

ID=27545138

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002208859A Abandoned CA2208859A1 (fr) 1995-01-13 1996-01-10 Utilisation de 3,4-diphenyl chromannes pour obtenir une composition pharmaceutique de traitement ou de prophylaxie de l'hyperlipoproteinemie, de l'hypertriglyceridemie, de l'hyperlipidemie, de l'hypercholesterolemie, de l'arteriosclerose, ou dans un traitement anticoagulant

Country Status (11)

Country Link
EP (1) EP0804189A1 (fr)
JP (1) JPH10511961A (fr)
CN (1) CN1168098A (fr)
AU (1) AU4329296A (fr)
BR (1) BR9606890A (fr)
CA (1) CA2208859A1 (fr)
CZ (1) CZ212397A3 (fr)
HU (1) HUP9800521A3 (fr)
IL (1) IL116745A (fr)
NO (1) NO973241L (fr)
WO (1) WO1996021443A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
AU3023999A (en) * 1998-03-20 1999-10-18 Novo Nordisk A/S Use of 3,4-diphenylchromans for the manufacture of a pharmaceutical composition for lowering plasma levels of lp(a) in a human or sub-human primate
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
CA2581316C (fr) 2004-09-21 2013-09-10 Novogen Research Pty Ltd Derives de chromane substitues, medicaments et utilisation a des fins therapeutiques
EP2635273B1 (fr) 2010-11-01 2020-01-08 MEI Pharma, Inc. Compositions d'isoflavonoïdes et méthodes de traitement du cancer
MX368063B (es) 2014-02-07 2019-09-18 Novogen ltd Compuestos de benzopirano funcionalizados y uso de los mismos.
CN116139125A (zh) 2015-02-02 2023-05-23 梅制药公司 联合治疗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1543749A1 (de) * 1966-02-16 1969-12-11 Merck Ag E Verfahren zur Herstellung von 3,4-cis-4-Aryl-isoflavanen
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
JPH10511961A (ja) 1998-11-17
CZ212397A3 (en) 1997-11-12
HUP9800521A2 (hu) 1998-12-28
BR9606890A (pt) 1997-10-28
IL116745A (en) 1999-12-22
HUP9800521A3 (en) 1999-12-28
AU4329296A (en) 1996-07-31
MX9705214A (es) 1997-10-31
IL116745A0 (en) 1996-05-14
EP0804189A1 (fr) 1997-11-05
NO973241D0 (no) 1997-07-11
NO973241L (no) 1997-07-11
WO1996021443A1 (fr) 1996-07-18
CN1168098A (zh) 1997-12-17

Similar Documents

Publication Publication Date Title
CA2157879C (fr) Methodes utilisant le 3,4-diarylchromane pour empecher la perte de substance osseuse
AU693628B2 (en) Use of 3,4-diphenylchromans
US5726202A (en) Benign prostatic hypertrophy
EP0873122B1 (fr) Utilisation de 3,4-diphenylchromannes dans la fabrication d'une composition pharmaceutique servant au traitement ou a la prophylaxie du cancer de la prostate
CA2208859A1 (fr) Utilisation de 3,4-diphenyl chromannes pour obtenir une composition pharmaceutique de traitement ou de prophylaxie de l'hyperlipoproteinemie, de l'hypertriglyceridemie, de l'hyperlipidemie, de l'hypercholesterolemie, de l'arteriosclerose, ou dans un traitement anticoagulant
CA2241556A1 (fr) Utilisation de 3,4-diphenylchromannes dans la fabrication d'une composition pharmaceutique servant au traitement ou a la prophylaxiede l'atrophie de la peau et/ou des membranes muqueuses
CA2241623A1 (fr) Utilisation de 3,4-diphenylchromannes dans la fabrication d'une composition pharmaceutique servant au traitement ou a la prophylaxie des symptomes menopausiques
US5886021A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis
WO1996022092A1 (fr) Utilisation des 3,4-diphenylchromanes pour la preparation d'une composition pharmaceutique destinee au traitement preventif ou curatif de l'obesite
WO1998033499A1 (fr) Utilisation de chromanes de 3,4-diphenyle pour la fabrication d'une composition pharmaceutique destinee a augmenter la libido chez les femmes en phase de post-menopause
CA2208868A1 (fr) Utilisation de 3,4-diphenyl chromannes pour obtenir une composition pharmaceutique servant au traitement ou a la prophylaxie de la gynecomastie idiopathique ou physiologique
WO1998033500A1 (fr) Utilisation de chromanes de 3,4-diphenyle pour la fabrication d'une composition pharmaceutique destinee a inhiber l'insuffisance motrice associee a la senescence
MXPA97005214A (en) Use of the 3,4-difenil-chromanos for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia or arterioesclerosis or for anti-treatment
KR19980701382A (ko) 고리포단백혈증, 고트리글리세리드혈증, 고지방혈증 또는 고콜레스테롤혈증, 또는 동맥경화증의 치료 또는 예방용 또는 항응고제 치료용 약학적 조성물의 제조를 위한 3,4-디페닐크로만의 사용
EP0921797A1 (fr) Emploi de 3,4-diphenyl chromans dans des preparations pharmaceutiques abaissant la tension intraoculaire
MXPA97005379A (en) Use of the 3,4-difenil-chromians for the manufacture of a pharmaceutical composition for treatment or profilaxis vasodilatad
MXPA97005219A (en) Use of 3,4-difenil-chromanos for the manufacture of a pharmaceutical composition for the treatment of profilaxis of disorders ginecologi
WO1999048497A1 (fr) UTILISATION DE 3,4-DIPHENYLCHROMANNES POUR LA FABRICATION D'UNE COMPOSITION PHARMACEUTIQUE DESTINEE A LA REDUCTION DES CONCENTRATIONS PLASMATIQUES DE Lp(a) CHEZ L'HOMME OU CHEZ DES PRIMATES
KR19980701383A (ko) 부인병 질환의 치료 또는 예방용 약학적 조성물의 제조를 위한 3,4-디페닐크로만의 사용(use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment of prophylaxis of idiopathic or physiologic gynaecomastia)

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20010110